Search the Newsreel

Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary

Aprea Therapeutics reported its second-quarter 2026 results, showing no revenue due to exhausted NIH grant funding, a net loss of $(3.59M), and a diluted EPS of $(0.07). The company is focusing on its WEE1 inhibitor, APR-1051, which has shown early proof-of-concept in clinical trials, …

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

Aprea Therapeutics announced its financial results for the second quarter ended June 30, 2026, reporting $41.2 million in cash and cash equivalents and an operating loss of $4.0 million. The company is accelerating enrollment in its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor …

Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Aprea Therapeutics Inc (APRE) has an earnings forecast score of 9.00, placing it highly within the Biotechnology & Medical Research industry. Analysts have set an average price target of $10.50, with a strong buy rating based on the consensus of 4 analysts. The company's …

Aprea Therapeutics Inc (APRE) Stock News Today

This article from TradingKey provides current news for Aprea Therapeutics Inc (APRE), indicating its stock price as $0.650 with a 2.81% increase. It highlights that more news will be available soon. The page serves as a hub for financial information, including quotes, news, analysis, …

Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

Aprea Therapeutics Inc is projected to report a loss of 23 cents per share. This information is part of an earnings preview, indicating financial analysts' expectations for the company's upcoming earnings report. The full article is available to TradingView subscribers.

Price to book forward of Aprea Therapeutics, Inc. – NASDAQ:APRE

This article provides financial information for Aprea Therapeutics, Inc. (NASDAQ: APRE), specifically focusing on its price-to-book forward ratio. The content is primarily a data placeholder from TradingView, indicating that specific value and change metrics for this financial ratio would be displayed in the designated …

Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

Aprea Therapeutics (Nasdaq: APRE) announced an update on its oral WEE1 inhibitor APR-1051 from the ongoing Phase 1 ACESOT-1051 trial. The company expects to present new clinical data in Q4 2026, with enrollment accelerating, active clinical sites increasing from three to ten, and an …

Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial

Aprea Therapeutics announced it expects to present clinical data from its Phase 1 ACESOT-1051 trial in Q4 2026. The trial, evaluating APR-1051 for advanced solid tumors, is expanding enrollment and will include combination regimens with standard-of-care therapies. The company anticipates completing dose escalation and …

Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis

Aprea Therapeutics Inc (APRE) currently has a valuation score of 8.59, ranking 110th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.42, which is significantly below its recent high and above its recent low. However, relevant …

Q&A: Aprea Therapeutics' Oren Gilad on WEE1 Inhibitor Data and the Company's DNA Damage Response Strategy

Oren Gilad, CEO of Aprea Therapeutics, discussed the company's WEE1 inhibitor, APR-1051, at BIO 2026, highlighting initial positive phase 1 data presented at ASCO 2026, including a confirmed partial response. APR-1051 is designed to minimize off-target effects compared to earlier WEE1 inhibitors, and Aprea …

Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk

Aprea Therapeutics Inc (APRE) has a current risk assessment score of 2.31, ranking it 220 out of 384 in the Biotechnology & Medical Research industry. The company's beta value of 1.46 indicates higher volatility compared to the S&P 500. The article details various risk …

Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Aprea Therapeutics Inc (APRE), focusing on its stock price momentum, support and resistance levels, and various technical indicators and moving averages. The stock currently has a price momentum score of 4.51 and is trading between a resistance …

Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis

Aprea Therapeutics Inc (APRE) currently holds a financial score of 6.51, ranking 248th out of 385 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue decreased by 100.00% year-over-year, and net profit declined …

Aprea Therapeutics Inc (APRE) - Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Aprea Therapeutics Inc (APRE) by TradingKey, assigning it a score of 6.15/10. The analysis highlights the company's healthy fundamentals and significant growth potential, despite a recent weak stock market performance. It notes a high institutional ownership …

Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Aprea Therapeutics Inc.'s (APRE) shareholder structure, listing major individual and institutional holders and their percentage of ownership. It also presents a historical overview of institutional shareholding, showing changes in the number of institutions and shares held over …

Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Aprea Therapeutics Inc (APRE). It states that no dividends have been distributed in the past five years and details multiple stock splits that occurred on February 10, 2023, all listed as a 20-to-1 merger. …

Aprea Therapeutics Inc APRE Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Aprea Therapeutics Inc (APRE), detailing operating, investing, and financing cash flows. It also includes an overview of cash flow concepts and answers frequently asked questions regarding operating, investing, financing, and free cash flow …

APRE|Aprea Therapeutics Inc|Price:0.620|Chg%:-0.012

Aprea Therapeutics Inc (APRE) is a clinical-stage biopharmaceutical company focusing on precision oncology, with its stock trading at $0.620. Despite a recent market downturn and a 67.17% fall over the past year, the company is rated a "Strong Buy" by analysts, with a target …

Aprea Therapeutics (NASDAQ: APRE) wins 180-day extension to meet $1 bid

Aprea Therapeutics (NASDAQ: APRE) has been granted an additional 180-day extension by Nasdaq, until January 19, 2027, to regain compliance with the minimum $1.00 bid price requirement for continued listing. The company previously had a deadline of July 22, 2026, and needs its common …

Aprea Therapeutics (APRE) Edges Higher with Modest Gains Amid Tight Trading Range - Bullish Pattern Stocks

Aprea Therapeutics(APRE) Stock Options Chain | Quotes & News

This article provides financial information for Aprea Therapeutics (APRE), including its stock options chain, quotes, and news. However, the content provided is blank, indicating no detailed information is currently available.